Title:
COMPOUND AS PARP7 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/188889
Kind Code:
A1
Abstract:
The present invention provides a compound as a PARP7 inhibitor. Specifically, the present invention provides is a compound having a structure as represented by formula (I) below, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate or solvate thereof. The compound can be used for treating or preventing diseases or disorders associated with the activity or expression level of PARP7.
More Like This:
Inventors:
ZHANG HANCHENG (CN)
JIA WEI (CN)
CAI CONGCONG (CN)
JIA WEI (CN)
CAI CONGCONG (CN)
Application Number:
PCT/CN2022/080732
Publication Date:
September 15, 2022
Filing Date:
March 14, 2022
Export Citation:
Assignee:
HANGZHOU INNOGATE PHARMA CO LTD (CN)
International Classes:
C07D403/12; A61K31/501; A61K31/506; A61P9/00; A61P25/28; A61P29/00; A61P31/12; A61P35/00; A61P35/02; C07D401/12
Domestic Patent References:
| WO2021113625A1 | 2021-06-10 | |||
| WO2021087018A1 | 2021-05-06 | |||
| WO2021087025A1 | 2021-05-06 | |||
| WO2020223229A1 | 2020-11-05 |
Foreign References:
| CN1558904A | 2004-12-29 | |||
| CN112424188A | 2021-02-26 | |||
| CN1729000A | 2006-02-01 | |||
| CN101855221A | 2010-10-06 |
Other References:
GOZGIT JOSEPH M.; VASBINDER MELISSA M.; ABO RYAN P.; KUNII KAIKO; KUPLAST-BARR KRISTY G.; GUI BIN; LU ALVIN Z.; MOLINA JENNIFER R.: "PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity", CANCER CELL, CELL PRESS, US, vol. 39, no. 9, 22 July 2021 (2021-07-22), US , pages 1214, XP086777352, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2021.06.018
Attorney, Agent or Firm:
XU&PARTNERS, LLC. (CN)
Download PDF:
Previous Patent: GARDEN TOOL HAVING BLOWING FUNCTION
Next Patent: CONDITIONAL HANDOVER METHOD, APPARATUS AND DEVICE, AND STORAGE MEDIUM
Next Patent: CONDITIONAL HANDOVER METHOD, APPARATUS AND DEVICE, AND STORAGE MEDIUM